lani, page-21

I have to say that it's easy to sit back and say that the price has risen not because of management but rather because of a good product that lacked marketing for years. But I still think the management over the years had to make the right calls to get in this position. Licensing out to large pharma (GSK in the case of Relenza) was an intentional strategy such that management didn't have to get involved in the day to day marketing.

It's a tough call to whether or not current management should be praised for previous management successes however this happens everywhere. One management team comes in and injects long term life into a company can leave well before there decisions bear fruit. We are yet to see the Laninamivir license deal but if even half my expecations are filled with regards to the deal then we should all be pretty happy campers.

Out of interest, does anyone know in what timeframe we can expect the Laninamivir license deal? Given large pharma were running the numbers back when Phase III was released you would think as early as end October is possible? Any ideas?